Literature DB >> 28286160

P2X7 receptor promotes intestinal inflammation in chemically induced colitis and triggers death of mucosal regulatory T cells.

Vanessa R Figliuolo1, Luiz Eduardo Baggio Savio2, Hanaa Safya3, Hayandra Nanini4, Cláudio Bernardazzi5, Alessandra Abalo6, Heitor S P de Souza5, Jean Kanellopoulos7, Pierre Bobé8, Cláudia M L M Coutinho9, Robson Coutinho-Silva10.   

Abstract

P2X7 receptor activation contributes to inflammation development in different pathologies. We previously reported that the P2X7 receptor is over-expressed in the gut mucosa of patients with inflammatory bowel disease, and that P2X7 inhibition protects against chemically induced colitis. Here, we investigated in detail the role of the P2X7 receptor in inflammatory bowel disease development, by treating P2X7 knockout (KO) and WT mice with two different (and established) colitis inductors. P2X7 KO mice were protected against gut inflammation induced by 2,4,6-trinitrobenzenesulfonic acid or oxazolone, with no weight loss or gut histological alterations after treatment. P2X7 receptor knockout induced regulatory T cell accumulation in the colon, as evaluated by qRT-PCR for FoxP3 expression and immunostaining for CD90/CD45RBlow. Flow cytometry analysis of mesenteric lymph node cells showed that P2X7 activation (by ATP) triggered regulatory T cell death. In addition, such cells from P2X7 KO mice expressed more CD103, suggesting increased migration of regulatory T cells to the colon (relative to the WT). Our results show that the P2X7 has a key role during inflammation development in inflammatory bowel disease, by triggering the death and retention in the mesenteric lymph nodes of regulatory T cells that would otherwise promote immune system tolerance in the gut.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATP; Colitis, regulatory T cells; P2X7 receptor

Mesh:

Substances:

Year:  2017        PMID: 28286160     DOI: 10.1016/j.bbadis.2017.03.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  23 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  Purinergic drug targets for gastrointestinal disorders.

Authors:  Geoffrey Burnstock; Kenneth A Jacobson; Fievos L Christofi
Journal:  Curr Opin Pharmacol       Date:  2017-11-14       Impact factor: 5.547

Review 3.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

4.  Effects of a P2X7 receptor antagonist on myenteric neurons in the distal colon of an experimental rat model of ulcerative colitis.

Authors:  Mariá Munhoz Evangelinellis; Roberta Figueiroa Souza; Cristina Eusébio Mendes; Patricia Castelucci
Journal:  Histochem Cell Biol       Date:  2021-10-09       Impact factor: 4.304

Review 5.  Pyroptosis and Its Role in Autoimmune Disease: A Potential Therapeutic Target.

Authors:  Ruixuan You; Xinglan He; Zhuotong Zeng; Yi Zhan; Yangfan Xiao; Rong Xiao
Journal:  Front Immunol       Date:  2022-05-25       Impact factor: 8.786

Review 6.  Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.

Authors:  Paola de Andrade Mello; Robson Coutinho-Silva; Luiz Eduardo Baggio Savio
Journal:  Front Immunol       Date:  2017-11-14       Impact factor: 7.561

Review 7.  The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Authors:  Luiz E B Savio; Paola de Andrade Mello; Cleide Gonçalves da Silva; Robson Coutinho-Silva
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

Review 8.  The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.

Authors:  Geoffrey Burnstock; Gillian E Knight
Journal:  Purinergic Signal       Date:  2017-11-21       Impact factor: 3.765

Review 9.  To Inhibit or Enhance? Is There a Benefit to Positive Allosteric Modulation of P2X Receptors?

Authors:  Leanne Stokes; Stefan Bidula; Lučka Bibič; Elizabeth Allum
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

Review 10.  Immunological Mechanisms in Inflammation-Associated Colon Carcinogenesis.

Authors:  Takehiro Hirano; Daisuke Hirayama; Kohei Wagatsuma; Tsukasa Yamakawa; Yoshihiro Yokoyama; Hiroshi Nakase
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.